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Zusammenfassung 
 
Der weltweite Anstieg koronarer Herzerkrankungen, insbesondere des akuten 
Myokardinfarkts (MI), welcher durch einen fortschreitenden Verschluss der Koronararterien 
hervorgerufen wird, stellt heutzutage eine der größten medizinischen Herausforderungen dar.  
Neue regenerative Ansätze, wie die vielversprechende Stammzelltherapie, werden benötigt, 
um die verminderten kardialen Funktionen des nekrotischen Myokards signifikant verbessern 
zu können. Insbesondere Stammzellen aus dem Knochenmark zeigen einen positiven Effekt 
auf die funktionelle Regeneration. Jedoch ist ihr Wirkmechanismus noch immer ungeklärt, 
wobei Transdifferenzierung, Fusion mit Kardiomyozyten oder parakrine Effekte diskutiert 
werden.  
Transmembran Rezeptor Tyrosinkinase CD117 (c-Kit) exprimierende Stammzellen (SZ) 
kommen sowohl im Knochenmark als auch im Herzen vor. Ihre Injektion in das infarzierte 
Herz verbesserte die kardialen Funktionen im Tiermodell. Als Reaktion auf eine ischämische 
Schädigung werden darüber hinaus CD117
+
 SZ aus dem Knochenmark zum Herzen 
rekrutiert. In murinen Tiermodellen erhöhten die infiltrierenden und kardialen CD117
+
 SZ die 
Expression des vaskulären endothelialen Wachstumsfaktors (VEGF) und etablierten somit ein 
pro-angiogenes Milieu in der Infarktrandzone. Andere präklinische Studien mit Tiermodellen 
weisen auf ein Transdifferenzierungspotential der CD117
+
 SZ in Kardiomyozyten hin. 
Dennoch ist die Expression kardialer Marker kein ausreichender Nachweis für eine 
Differenzierung in einen kardialen Zelltyp. Der Nachweis sollte durch die Detektion und 
Messung funktionaler und zellspezifischer Ionenkanäle erbracht werden. Dieser Arbeit wurde 
die elektrophysiologische Charakterisierung von CD117
+
 SZ zu Grunde gelegt, da sie 
entscheidend für die Sicherheit der implantierten Zellen (Vermeidung von Arrythmien) und 
deren elektrophysiologische Kopplung an das aufnehmende Myokard ist. Trotz der vielfachen 
Verwendung von murinen CD117
+
 SZ in in vivo Studien, sind ihre Ionenkanäle noch 
unzureichend erforscht. Wir passten in dieser Arbeit die Patch-Clamp Methodik für CD117
+
 
SZ an und konnten somit ihre Differenzierung in einen endothel-ähnlichen Phänotyp zeigen 
und gleichzeitig eine Differenzierung in vaskuläre glatte Muskelzellen oder Kardiomyozyten 
ausschließen. Im Mausmodell bewirkte die intramyokardiale Applikation von CD117
+
 SZ 
eine signifikante Verbesserung der Kapillardichte, der Kollagenablagerung und der Links-
Ventrikulären Funktionen drei Wochen nach induziertem MI.  
Ein weiterer Schwerpunkt der Arbeit lag beim Renin-Angiotensin System, insbesondere beim 
Angiotensin II Typ-2 Rezeptor (AT2R), der Signale des aktiven Metaboliten Angiotensin II 
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weiterleitet und dem Angiotensin II Typ-1 Rezeptor (AT1R) entgegenarbeitet. In der 
kardialen Regeneration bewirkte eine Stimulation des AT2R eine Kardioprotektion durch die 
Inhibierung von Inflammation und Apoptose und verbesserte das myokardiale Remodeling in 
verschiedenen Studien mit Tiermodellen 
Die indirekte Stimulation muriner CD117
+
 SZ für den AT2R ermöglichte uns, Effekte auf die 
kardiale Regeneration in vitro und in vivo zu erforschen. Einen wesentlichen Beitrag der 
Stimulation konnten wir durch eine vermehrte Zellanordnung und einem erhöhten Länge-zu-
Breite Verhältnis in einem 2-D Angiogenese Experiment beobachten. Ionenkanäle und 
gemessene Ströme änderten sich nur geringfügig, was besonders durch einen gesteigerten 
einwärts-gleichrichtenden Kaliumkanal und dessen erhöhter mRNA Expression  deutlich 
wurde. Die Ergebnisse der ausgeführten in vivo Studie wurden durch eine AT2R Stimulation 
nicht beeinflusst. Wir vermuten, dass die sehr komplexe Regulation des AT2R und seine 
Interaktion mit dem entgegenwirkenden AT1R eine tragende Rolle spielt. 
Zusammenfassend kann das Regenerationspotential der CD117
+
 SZ parakrinen Effekten, wie 
der Ausschüttung von VEGF und der Differenzierung in einen endothel-ähnlichen Phänotyp 
zugeschrieben werden. Eine Transdifferenzierung der Zellpopulation in Kardiomyozyten 
muss auf Grundlage der gewonnenen Erkenntnisse ausgeschlossen werden. Dennoch konnten 
wir am Kleintiermodell zeigen, dass die intramyokardiale Gabe der CD117
+
 SZ eine sichere 
Applikationsmethode ist und diese Zellpopulation eine therapeutische Wirksamkeit im Sinne 
einer funktionellen Verbesserung des geschädigten Herzens ausübt.  
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Summary 
 
The worldwide increasing incidence of coronary heart diseases, particularly acute myocardial 
infarction, evoked by progressive coronary atherosclerosis, is one of the major medical 
challenges nowadays.  
New regenerative approaches are needed to restore the loss of cardiac function in the necrotic 
myocardium. Stem cell therapy is one of those promising novel approaches. Numerous 
studies exist that involve varying delivery sites and methods as well as different types of stem 
cells. Especially bone marrow stem cells (BMSC) showed a beneficial effect on functional 
regeneration, but their mechanism of action is still debated and ranges from 
transdifferentiation to fusion or paracrine effects. Stem cells (SC) expressing the 
transmembrane receptor tyrosine kinase CD117 (c-Kit) were found in the bone marrow and in 
the heart. Their implantation improved cardiac functions after myocardial infarction in animal 
models. In response to cardiac damage CD117
+
 SC are also recruited from the BMSC pool 
towards the infarcted heart. In murine animal studies, infiltrating and resident CD117
+
 SC 
increased the expression of vascular endothelial growth factor and in this way established a 
pro-angiogenic milieu in the infarct border zone. Other animal studies claim a 
transdifferentiation potential of CD117
+
 SC into cardiomyocytes. Nevertheless, the protein 
expression of cardiac markers, often shown to verify the differentiation of cells into a specific 
cell type, does not prove a functional differentiation. This should rather be assessed by the 
expression of functional and appropriate ion channels. We assessed that electrophysiological 
properties of implanted cells are crucial in terms of safety and to predict the electrical 
coupling to host cells. Interestingly, ion channels of freshly isolated murine CD117
+
 BMSC, 
especially prior to implantation still lack proper descriptions. In the work presented here we 
show the differentiation of murine CD117
+
 SC into an endothelial-like (nonexcitable) 
phenotype. We could clearly distinguish them from vascular smooth muscle cells or 
cardiomyocytes. Results were obtained using whole-cell patch-clamp and a range of 
molecular biological techniques. In vivo, the intramyocardial application of CD117
+ 
SC 
significantly improved capillary density, collagen deposition and left ventricular functions 
three weeks after experimentally induced myocardial infarction.  
A further interest of this work was the renin-angiotensin system, particularly the angiotensin 
II type-2 receptor (AT2R), which mediates actions of the active metabolite angiotensin II and 
opposes effects of the angiotensin II type-1 receptor. In cardiac regeneration, the AT2R acts 
cardioprotective, displayed by anti-inflammatory and anti-apoptotic effects and improved 
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myocardial remodeling in animal studies. The finding of a cell population positive for AT2R 
and CD117 provides a potential option for new stem cell therapy. In this project we indirectly 
stimulated murine CD117 BMSC for the AT2R to dissect beneficial effects in vitro and in 
vivo. One major contribution was seen in the enhanced cell alignment and increased 
elongation ratio in a 2-D angiogenesis assay. Ion channels and assessed currents changed only 
moderately under AT2R stimulation, which was revealed by an increased inward rectifying 
potassium current (IKir) and increased IKir mRNA expression. Therefore, electrophysiological 
and molecular properties of control and AT2R-stimulated cells point to a differentiation to 
vascular endothelial cells. In vivo outcomes were not challenged by an additional stimulation 
of CD117
+
 SC, which might be due to the complex regulation of AT2R and the interplay with 
its opposing receptor.  
In summary, a regenerative potential of the CD117
+
 SC population might be attributed to 
enhanced paracrine effects, such as the excretion of VEGF and their differentiation into an 
endothelial-like phenotype. The transdifferentiation of CD117
+
 SC has to be excluded here. 
However, this work using a small animal model shows that the implantation of those cells is 
safe and contributes to functional improvements of the damaged heart.  
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Introduction 
 
1 Incidence and pathophysiology of myocardial infarction 
 
One of the challenges of the twenty-first century is the increasing burden of organ failure in 
an aging population, especially caused by cardiac diseases. Despite substantial progress in the 
treatment of coronary heart diseases, 7.3 million people died of heart failure in 2008, a 
number, which will continuously rise especially in low-income countries [1]. The most 
common cause of acute myocardial infarction (MI) is a coronary occlusion due to progressive 
coronary atherosclerosis and thrombus formation. Coronary occlusion results in an 
insufficient supply of oxygen and nutrients and a subsequent death of myocytes in the 
affected area of the heart. In most cases the left ventricle is affected, since its muscle layer is 
thicker than the right ventricle and energy consumption is higher. The infarcted and the 
unaffected myocardial regions undergo progressive changes, which are determined by the 
magnitude of myocytes loss, the stimulation of the sympathetic nervous system, the 
stimulation of the renin-angiotensin-aldosterone system and the release of natriuretic peptides 
[2].  The subsequent phases of cardiac wound healing in the humans are 1) myocytes cell 
death due to necrosis and apoptosis 2) acute inflammation 3) granulation tissue and scar 
formation and 4) remodeling of the left ventricle. Myocyte cell death usually develops in the 
subendocardium and broadens towards the epicardium until it spans the entire ventricular 
wall. If blood flow can be restored in time, reversibly damaged areas at the edges of the 
infarcted area (stunned myocardium) can recover even without an inflammatory reaction [3]. 
In irreversibly damaged areas, the inflammatory response is the prerequisite for healing and 
scar formation [4]. Following myocyte death and the subsequent release of cytokines, 
inflammatory cells, especially phagocytic neutrophils, enter the infarct area.  Infiltrating 
granulocytes, lymphocytes and macrophages follow, which release cytokines, growth factors 
and proteases [5]. Moreover, macrophages and fibroblasts engulf the necrotic tissue and make 
up the granulation tissue [6]. Maturing of the granulation tissue is associated with scar 
formation including fibroblast proliferation and collagen deposition. The developed scar 
tissue stabilizes the infarcted area, but cannot actively contribute to the pumping of the heart. 
This phenomenon negatively influences the mechanical stress of the intact tissue leading to 
adaptive compensatory changes in affected cardiac cells termed hypertrophy. It is 
characterized by an enlargement of myocytes to compensate for the diminished cardiac 
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functions and to attenuate progressive dilatation [7]. In the long run hypertrophy decreases 
resilience of cardiomyocytes, provokes progressive dilation of the ventricle and deterioration 
of contractile functions. This remodeling process alters the ventricular architecture as the 
heart aims to normalize the increased wall stress. Together, the mechanism of hypertrophy, 
the increased fibrosis as well as collagen deposition and the loss of contractile tissue lead to 
ventricular stiffness and dysfunction. Eventually, the chronic usage of compensatory 
processes leads to chronic heart insufficiency and cannot save the infarcted heart.  
Depending on the localization of the thrombus and on the duration of the occlusion, MI, 
which causes heart failure, may wipe out up to 25% of the 2-4 billion cardioymyocytes of the 
human left ventricle [8]. In contrast to zebrafish or some urodele amphibians, such as newts, 
humans are incapable of true cardiac regeneration after a major injury. Thus, state-of the art 
therapies range from drugs, such as antiplatelet drugs, angiotensin-converting enzyme 
inhibitor or beta-adrenergic blocking agents to surgical procedures providing reperfusion (e.g. 
Angioblasty, Coronary Artery Bypass Graft or Coronary stenting) and eventually to heart 
transplantation. However, organ supply is limited to a very small minority of patients.  
Available drugs and invasive therapies need to be supported or superseded by novel 
therapeutic approaches, like tissue engineering or cell therapies that restore tissue function 
and are available for the majority of patients. Due to ethical and practical reasons it is out of 
question to test new diagnostics and therapeutic approaches in human beings. Approaches for 
2D and 3D-cell culture models exist, but they lack the reproduction of microenvironment, 
especially the complex immune response [9]. Currently, experimental MI in animal models is 
indispensible to simulate the pathophysiology of an infarcted heart and to subsequently 
develop new successful therapies. Yet, it has to be taken into account that species and gender 
of the laboratory animal influences the pathophysiology of induced MI. Certain limitations, 
such as the small size of the heart and structural differences compared to the human heart 
should be considered when using mouse models and transferring results to human. 
Nevertheless, major advantages include the existence of transgenic and knockout mouse 
strains, ease of genetic modifications, handling and breeding [10]. To gain further insights 
into the pathophysiology of post-MI and into its molecular basics, mouse models are an ideal 
and established tool [11, 12].  
The small animal model of MI can be evaluated by determining changes in cardiac functions 
in vivo using catheter-conductance method [13]. The application of an indwelling catheter in 
the left ventricle (LV) of mice offers the possibility to generate pressure-volume relationships, 
which are independent of the LV chamber geometry and highly accurate despite the rapid 
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heartbeat [14]. Important parameters are 1) the ejection fraction, which gives the percentage 
of change in ventricular volume in one heartbeat; 2) the cardiac output, which is the volume 
of blood (stroke volume) the heart pumps per minute (heart rate) and 3) the developed 
maximum pressure or the first derivative of intraventricular pressure (dp/dt) [15].  
 
2 Growth and remodeling of blood vessels 
 
The adaptation of blood vessels is a component of myocardial remodeling and a potential 
target of therapeutic strategies. The functional restoration of damaged tissue is dependent on 
the re-establishment of collateral networks and subsequent supply of the energy demanding 
myocytes with oxygen and nutrients.  Tissue ischemia and dilatation of existent blood vessels 
induce the upregulation of angiogenic growth factors and the mobilization of circulating cells 
that stimulate cardiac vessel growth. Favorable vessel formation in tissue ischemia involves 
the three main processes of neovascularization: vasculogenesis, angiogenesis and 
arteriogenesis [16, 17]. Vasculogenesis broadly comprises the de novo formation of blood 
vessels and is responsible for earliest blood vessel formation during embryonic development. 
Endothelial progenitor cells (EPC) migrate towards the region of vascularization and 
differentiate into mature endothelial cells (EC) that form the primary vascular plexus and the 
later vascular network [18]. Current research demonstrated that vasculogenesis also 
contributes to the vascular remodeling process elicited by pathological conditions, such as 
wound healing or ischemic injury, in the adult organism. In this regard, increasing numbers of 
circulating EPC were detected shortly after MI in the peripheral blood [19].  
Angiogenesis is defined as the sprouting of new capillaries from pre-existent blood vessels by 
EC proliferation and migration resulting in new capillary networks [20, 21]. The development 
of new capillaries either divides a vessel into two parts or forms new branches and is driven 
by a growth factor gradient. The major stimulus of angiogenesis is hypoxia leading to the 
upregulation and accumulation of hypoxia-inducible-factor 1 (HIF 1), a transcription factor 
that regulates oxygen homeostasis [22]. HIF-1 regulates the expression of angiogenic growth 
factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF) and angiopoietin, which in turn activates EC as well as vascular smooth muscle cell 
migration, proliferation and vessel enlargement [20, 23].  
The term arteriogenesis refers to the process of maturation and outgrowth of pre-existing 
collateral arteries or their de novo growth to bypass arterial stenosis in response to 
 15 
 
hemodynamic changes. Shear stress and the subsequent local activation of endothelium are 
the initial trigger of arteriogenesis, which typically occurs outside the area of ischemia and 
was found to be independent of the tissue oxygen level [24]. The stimulated EC release 
adhesion molecules and chemokines, attracting blood-derived monocytes, which secrete 
growth factors (VEGF, bFGF and platelet-derived growth factor), cytokines and matrix-
degrading enzymes [16, 25, 26]. Arteriogenesis further involves basal membrane degradation, 
proliferation of vascular cells (endothelial and smooth muscle) and structural remodeling of 
the extracellular matrix [25].  
 
3 Definition and properties of stem cells  
 
Since their discovery more than a century ago, the research on stem cells (SC) has come a 
long way and offers many therapeutic approaches for various diseases. Their inherent 
characteristics make them promising candidates for extensive usage and distinguish them 
from somatic cells.  A stem cell is defined by its ability to self-renew through cell division 
even after long periods of inactivity and its ability to differentiate into a range of more 
specialized progenitor cells that eventually give rise to functionally mature cells. Moreover, in 
contrast to most somatic cells, SC show telomerase activity, which enables them to proliferate 
for an unlimited time span [27]. The division of SC occurs either symmetrically (emerging of 
two uniform SC or two uniform specialized cells) or asymmetrically (emerging of one stem 
cell and one more specialized progenitor cell), a decision crucial for homeostasis and tissue 
maintenance.  
By now, SC were detected in almost any tissue or organ. Under normal conditions, SC are 
needed to preserve the normal cell turnover and replenish specialized cells lost through minor 
injuries in tissues, such as skin, bone marrow (BM) and intestine.  
Types of SC can be divided either by their potency or by their tissue of origin. The potency of 
a stem cell is the capacity to differentiate into specialized cell types. A totipotent cell can 
differentiate into embryonic and extraembryonic cell types and thus, give rise to a complete 
organism [28]. During embryonic development, from the morula stage onwards, cells lose 
their totipotency and become pluripotent. Pluripotent cells have the potential to develop into 
any specialized cell type of the adult organism and to generate all cell types of the three germ 
layers, except of the trophoblast (giving rise to the placenta) [29]. Pluripotent SC differentiate 
into multipotent progenitor cells. Those multipotent cells can develop into a number of 
different cell types, but are thought to be committed to a specific germ layer and produce a 
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closely related family of cells. Hematopoietic stem cells (HSC), for example, are considered 
multipotent as they are able to give rise to all types of blood cells [28, 30]. Finally, unipotent 
cells reflect the lowest potency. These cells are able to self-renew and replenish cells of a 
single lineage in the adult tissue, meaning that they are already committed to a tissue.  
The origin divides SC into embryonic and adult stem cells. The possibility of reprogramming 
specialized adult cells into a state that closely resembles embryonic stem cells (ESC) gave rise 
to another stem cell type: induced pluripotent stem cells (iPSC) [31].  
 
3.1  Adult stem cells 
 
Adult stem cells (ASC) are present in most of the tissues of the human body and are also 
referred to as somatic SC. Their primary role is to maintain the tissue in which they are found, 
such as brain, spinal cord, digestive system, liver, pancreas or heart. Most ASC are lineage 
restricted and thus, multipotent. However, few types of ASC, such as cord blood stem cells 
are possibly pluripotent and display plasticity between the germ layers. Among others, this 
transdifferentiation phenomenon was even reported for adult BMSC differentiating into  
cardiomyocytes in vitro [32].  ASC reside in a specific area of each tissue, the cellular niche, 
which determines their survival, quiescence and activation [33]. Self-renewal and the balance 
between maintenance of the stem cell pool and production of progenitor cells engaged in 
tissue differentiation [34] is regulated by developmentally conserved signaling pathways: 
Notch [34], Wingless-type (Wnt) [35, 36], Sonic hedgehog (Shh) and Smad [37, 38].  
The major source of ASC is BM, which harbors mesenchymal stem cells (MSC) and HSC. 
Recently, both stem cell types have received increasing attention concerning their potential 
for stem cell therapy. In contrast to ESC or iPSC, not a single incidence of oncogenic 
transformation has been reported for bone marrow stem cells (BMSC) [39].  
 
3.2 Hematopoietic stem cells 
 
The existence of SC in BM was already proven in 1963 by the pioneering studies on the blood 
regenerating system by Till and McCulloch [40]. Within the hematopoietic system HSC are 
the only cell population capable of self-renewal and multi-potency. During bone marrow 
transplantation studies, it was shown that HSC are crucial for long-term engraftment and 
reconstitution [41]. In fact, HSC have the potential to differentiate into all functional blood 
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cells [42]. Most of those HSC-derived blood cells arise and mature in BM. In a healthy adult, 
a small population of HSC produces the enormous number of 500 billion blood cells every 
day, demands that require strict control over hematopoietic progenitor proliferation [43].  
For maintenance of the hematopoietic system, HSC must balance symmetric and asymmetric 
cell division, a process that requires the stem cell niche [33, 38]. HSC that lose contact to their 
niche progress towards a more differentiated state. The complex niche is a three-dimensional 
scaffold in the space between the vessels and the endosteum of the BM and consists of 
various cell types of which some are only recently elucidated. Non-hematopoietic 
(osteolineage cells, MSC, endothelial and perivascular cells and adipocytes) and 
hematopoietic (osteoclasts, macrophages and neutrophils) cellular components, together with 
cell-autonomous mechanisms, regulate HSC self-renewal, quiescence and responses to  
environmental signals [43]. The question how the niche directs self-renewal and 
differentiation of HSC remains. It was shown that niche compartments, especially osteoblasts 
and MSC, secrete cytokines and chemokines, such as granulocyte-conlony stimulating factor, 
granulocyte macrophage-colony stimulating factor, stem cell factor ligand (SCF) and 
CXCL12 (SDF-1), which influence HSC fate [35]. In this regard, and considering the 
recruitment of HSC to injured ischemic tissues, mobilization (recruitment) and homing are 
two mirror processes of major importance for future stem cell therapy [44]. By now it is 
known that the CXCR4/CXCL12 axis is a central regulator of HSC migration and retention. 
CXCL12 recruits CXCR4 expressing stem cells including HSC, EPC, CSC and MSC [45]. 
The presence of those chemokines influences if HSC leave the BM, enter the circulation, 
relocate to distant tissue (recruitment) or, eventually, return to the BM (homing) [46, 47]. The 
recruitment of stem and progenitor cells in the disease state of MI is also influenced by 
endothelial nitric oxide synthase (eNOS) and its generation of nitric oxide (NO) [48]. An 
increased eNOS expression in the tissue is associated with an enhanced migratory capacity of 
HSC and improved neovascularization. Moreover, eNOS expressing cells were found to 
contribute to the long-term effects of bone marrow cells in regenerative approaches [49]. 
Interestingly, mice lacking eNOS showed reduced VEGF-induced mobilization of EPC [50].  
The analysis of peripheral stem cell migration using the elegant technique of intravital 
microscopy applied to the mouse cremaster microcirculation was recently described by our 
group [51]. This technique will contribute to enlighten necessary microenvironmental 
preconditions to enhance rolling and adhesion of intravascularly administered SC at the 
endothelial lining.  
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3.3 CD117 (c-Kit) stem cells 
 
One marker to characterize HSC in mice and humans is the transmembrane receptor tyrosine 
kinase CD117 (c-Kit). In concert with its ligand SCF, CD117 plays an important role in HSC 
function and senescence. CD117 belongs to the type III receptor tyrosine kinase family and 
was highly conserved during evolution. The structure of CD117 consists of four domains: an 
extracellular domain, a transmembrane domain and an intracellular domain. The latter is split 
in a juxta-membrane domain and a tyrosine kinase domain by an insert region. The 
extracellular domain contains five immunoglobulin-like (Ig-like) domains. The first three Ig-
like domains are binding sites for a SCF molecule and are left unaltered upon binding, while 
the last two domains in the membrane proximal region establish the contact between two 
activated CD117 receptor  molecules [52]. The juxta-membrane domain interacts with the 
kinase domain and regulates its catalytic activity by stabilizing an inactive configuration, thus 
“autoinhibiting” the receptor [53]. SCF is a heavily glycosylated transmembrane protein that, 
following cleavage, exists in two forms with different effects on CD117 autophosphorylation: 
a membrane associated (sustained phosphorylation) or soluble (transient phosphorylation) 
form [54]. The simultaneous binding of dimeric SCF to two CD117 monomers results in 
receptor dimerization and subsequent activation of intrinsic tyrosine kinase activity and 
downstream signal transduction [55]. Following activation, tyrosine residues, primarily 
outside the kinase domain, become phosphorylated and function as docking sites for 
intracellular signal transduction molecules. Activation of the Ras/ERK1/2 pathway and the 
following transcription factors is of critical importance for cell division and survival as well 
as hematopoietic cell differentiation and  migration [56]. Furthermore, the activated Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway 
regulates cell proliferation, differentiation and apoptosis. Direct association of CD117 and 
PI3K (Phosphoinositide 3'-kinase) signaling is required for most SCF-mediated responses. 
Among others, this pathway mediates SCF-induced chemotaxis and Ca
2+
 mobilization, 
adhesion, actin assembly, proliferation and also anti-apoptotic signaling via the activation of 
AKT [57, 58]. Moreover, CD117 activation triggers SFK pathway activation functioning in 
cell cycle progression, chemotaxis, adhesion, survival, and protein trafficking and plays an 
important role in ligand-induced internalization of the receptor [59]. Other activated pathways 
include the Src kinase signal transduction pathway related to cell survival, angiogenesis, 
proliferation, motility and migration and the PLC-γ pathway involved in cell proliferation and 
Ca
2+
-release [60]. The multiple pathways influenced by CD117-SCF require negative 
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regulation as achieved by PKC family, the tyrosine phosphatase SHP1, the ubiquitin ligase 
Cbl and the phosphatase SHIP [54]. Interestingly, CD117 was found to be required for 
terminal cardiomyocyte differentiation [61] and is crucial for EC recruitment as well as 
neovascularization [62].  
In humans and mice, CD117 is widely distributed and expressed on various cells, such as 
HSC, germ cells, mast cells, EC, CSC, cardiomyocytes, glandular breast epithelial cells and 
Cajal cells in the gastrointestinal tract [63]. The receptor is found on 1 - 4 % of BMSC in 
healthy individuals and 60-75 % of CD34
+
 HSC [64].  
 
4 Stem cell therapy for cardiac regeneration 
 
At the beginning of the 2000s the detection of cardiac stem cells (CSC), distinct from bone 
marrow hematopoietic stem cells, has challenged the perspective of cardiac biology [65]. The 
existence of SC in the heart implicated that the physiological cell turnover of cardiac cells is 
regulated by differentiation of CSC. Consequently, the heart can be partly considered as a 
self-renewing organ, in which resident SC are at least able to replace old, dying cells in the 
absence of injury [66]. Moreover, it was proven recently that genesis of cardiomyocytes 
occurs at a low rate (only up to 1% per year in young adults) by the division of pre-existing 
cardiomyocytes. Cardiomyocyte cell-cycle activity was detectable during normal ageing and 
injury [67, 68]. However, the potential of resident SC and cardiomyocyte turnover for 
regeneration is not clinically relevant and cannot prevent the adverse remodeling processes of 
the heart emerging from MI. Moreover, the loss of cardiac function in the necrotic 
myocardium cannot be restored with conventional therapeutical options [69]. Therefore, the 
field of regenerative medicine and stem cell therapy aims to improve regeneration of injured 
tissue by the delivery of SC. 
Regenerative approaches aiming at a robust therapy to regenerate lost myocardium are 
numerous and involve varying delivery sites and methods as well as different types of SC, 
thought to possess progenitor features. Stem cell populations delivered include adult 
progenitor cells, such as bone marrow mononuclear cells (BMNC) [70-72], CD133+ cells [73, 
74], MSC [75], resident CSC [76-78] and skeletal myoblasts [79, 80] as well as ESC [81] and 
iPSC [82, 83]. Interestingly, any cell type proved to have at least some beneficial effect on 
regeneration - a finding that complicates the revealing of the underlying mechanisms [8]. By 
now it is controversially discussed if BMSC are able to truly transdifferentiate into mature, 
 20 
 
functional cardiomyocytes that electromechanically couple to host myocytes in vivo. 
However, expecting a paracrine effect of these cells in terms of increasing and provoking 
neovascularization in the injured heart makes them promising candidates for patient-specific 
cell therapy [84-86].  
Other studies challenge the clinical safety and point out the need for further sound 
investigations. MSC transplanted into the heart developed bone structures [87] and 
implantation of skeletal myoblasts or MSC  might lead to the development of arrhythmias 
[80]. Even though electromechanical coupling of implanted cells is not the prerequisite for an 
improved function, the possibility of misdirected electrical signaling has to be investigated 
prior to clinical testing.   
 
4.1  CD117
+
 stem cells for cardiac regeneration 
 
The many identified cardiac stem and progenitor cell types include CSC positive for CD117
+
 
cell surface antigen. In terms of feasibility, the isolation of CD117
+
 SC from the BM is 
superior to cardiac CD117
+
 retrieval. A certain regenerative potential of CD117
+
 (mice, 
human) or c-Kit
+
 (rats) SC has been demonstrated in vivo, but the underlying mechanisms are 
still debated. In response to cardiac damage, the CD117
+
 cells in the heart are not only 
resident CSC, but are additionally recruited from the BM stem cell pool [47, 88]. After being 
recruited to the infarcted heart, infiltrating and resident CD117
+
 SC increase the expression of 
VEGF and, in this way, establish a pro-angiogenic milieu in the infarct border zone. The 
mobilization of CD117
+
 SC in infarcted adult heart was reported to result in extensive 
angiogenesis, but they appeared incapable of cardiac myogenesis [89]. Various cell 
transplantation experiments also claim a differentiation potential for those BM-derived SC 
into “cardiomyocytes,” followed by improved cardiac functions [76, 90]. However, the 
findings of newly formed “cardiomyocytes” often turned out to be too optimistic, as those 
“cardiomyocytes” are either immature or eventually died by apoptosis [78]. Tallini et al. 
(2009) provided evidence that the CD117
+
 SC from murine neonatal heart can differentiate 
into cells of 3 cardiovascular lineages [91]. Of note, their study showed that CD117 re-
expression in the injured adult heart is associated with reduced cardiac injury, but not 
myogenesis, and is solely activated by local conditions, such as hypoxia and inflammatory 
cytokines. Xaymardan et al. (2009) showed that HSC, but not MSC, have the ability to form 
beating clusters [92]. The group also reported the potential of CD117
+
 BMSC to induce 
myogenic differentiation in short-term culture. However, the formation of a mature 
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cardiomyocyte phenotype was not achieved with CD117
+
 cells under those culture conditions. 
Unfortunately, impressive in vitro results, claiming a transdifferentiation of those cells, are 
often not reproducible using in vivo settings [85, 93]. Several studies were conducted that 
employed rodents as the animal model of choice showing a functional improvement, which 
does not necessarily correlate with increased regeneration. It could be rather due to reduced 
inflammation and further protection against adverse remodeling. The direct comparison and 
translation to humans is hampered, because of their distinct nature and hydrodynamics. 
Another debated point is the possible mechanism of action that either changes a CD117
+
 CSC 
or BMSC into a (mature) cardiomyocyte or that provokes improved cardiac functions. 
Possible mechanisms include transdifferentiation [32, 94], cell fusion with mature 
cardiomyocytes [93, 95], or paracrine effects, specifically the stimulation of angiogenesis and 
myogenesis in the infarcted region [85, 88, 96-98]. Owing to the existent controversies on 
CD117
+
 SC, this study first of all, aimed to investigate the behavior of those cells in terms of 
differentiation, angiogenesis and electrophysiological potential in vitro.  
The previously reported phenomenon of transdifferentiation of adult cells remains 
questionable mostly due to methodological problems. Especially the process of cell labeling 
and tracking is discussed to produce false-positive or false-negative detection of implanted 
cells. Errors might occur by dilution of cell staining dye during cell division or cell-to-cell 
transfer of either staining dye (e.g. through gap junctions) or of transfected vectors inducing 
expression of detectable proteins [99]. To overcome these problems, sex-mismatched 
transplantation, the usage of transgenic animals or advanced imaging technologies such as 
position emission tomography have been described [100]. Moreover, the detection of 
transdifferentiation might be caused by the fusion of host adult cells with transplanted SC. In 
the present work, the challenge of cell detection was approached by using transgenic mice, 
expressing EGFP in all nucleated cells as cell donor. The apparent problem of low cell 
retention after intramyocardial cell injection was taken into account by using BD Matrigel™ 
as an extracellular matrix. BD Matrigel™ is a solubilized basement membrane preparation 
extracted from Engelbreth-Holm-Swarm mouse sarcoma, a tumor rich in extracellular matrix 
proteins. It is liquid at four degrees and solidifies quickly after implantation. However, the 
injection of Matrigel™ is restricted to animal models.  
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5 The Renin-Angiotensin System and its receptors 
 
The renin–angiotensin system (RAS) interferes with inflammation and acute cardiac 
remodeling processes during cardiac injury. This endocrine system consists of a cascade of 
enzymes and hormones, involved in the regulation of blood pressure and electrolyte re-
absorption. The actions of two important enzymes, renin and angiotensin converting enzyme 
(ACE), contribute to produce the active metabolite angiotensin II (Ang II). Ang II can bind to 
its distinct receptors (AT1R, AT2R) with the same affinity [101]. Several pharmacological 
agents are available to interact with this complex peptidergic system, for instance, ACE 
inhibitors (e.g. captopril) and AT1 receptor blockers (ARB) (e.g. Losartan potassium). It was 
shown that myocardial hypoxia is associated with an increased activation of RAS, increased 
Ang II concentration and an increased expression of Ang II receptors [102-104].  
The octapeptide Ang II is one of the most important regulators of physiological and 
pathological processes in the cardiovascular system. Two Ang II receptor subtypes, namely 
AT1R and AT2R, have been characterized so far. Although both receptors have long since 
been identified [105], it was generally speculated that the AT2R fulfills only minor functions 
that complement the AT1R-mediated actions. This notion was challenged by the recent 
findings of hidden opposing functions of the AT2R.  
The two receptor subtypes share only 34% homology, and belong to the seven transmembrane 
G-protein coupled receptor family [101, 106]. Moreover, both receptor subtypes show a very 
distinct expression and regulation pattern as well as different signaling pathways. Activation 
of the AT1R by Ang II triggers vasoconstriction and sodium re-absorption and influences cell 
growth and apoptosis. Importantly, stimulation of AT1R is associated with cardiomyocyte 
hypertrophy, tissue damage, inflammation, and negative tissue remodelling [101, 107]. Until 
now, it was generally accepted that AT2R is highly expressed in fetal tissue. In adult human, 
mice and rats, expression seems to be restricted to certain cell types and tissues. The low 
AT2R expression in adults can be re-expressed under pathological conditions, such as stroke 
or myocardial infarction [101, 108-111]. Thus, the distinct tissue distribution and expression 
pattern of AT2R point to its potential role in development and differentiation, as well as tissue 
regeneration. Interestingly, this common assumption is challenged by the finding of Gao et al. 
(2012), who describe a higher expression of AT2R in adult than in fetus in contrast to AT1R 
[112]. They argue that the accepted dogma was solely based on observations in the skin and 
not verified for other organs. In their study, they discussed protein expression and validated 
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their findings in mice and rat [113]. If their results can be reproduced the current view on 
AT2R regulation, maturation and function has to be re-evaluated.  
Research on the AT2R is conducted mainly indirectly, and previous investigations are based 
on transgenic animals or AT1R and AT2R antagonists [114, 115]. In 2004, a selective 
nonpeptide, Compound21 (Co21), was developed as the first AT2R agonist [116]. Co21 is 
assumed to have selective affinity, excluding AT1R activation, and allowing researchers to 
explore AT2R mediated actions [116]. The obtained results pointed to a very complex and 
often unconventional receptor signaling, implying constitutive receptor activation [117, 118]. 
AT2R pathways are either mediated by G-proteins or are G-protein independent. The 
activation of Src homology region 2 domain-containing phosphatase 1 is a G-protein 
independent signaling pathway and involves the physical association to AT2R [119, 120]. The 
activation of such phosphatases and the subsequent inactivation of kinases seem to be the 
main effects of AT2R signaling, which influence the actions of growth factors, cytokines, and 
the AT1R. AT2R controls proliferation and the inflammatory actions of kinases, such as 
MAPK or JAK in certain cell lines [119]. Anti-inflammatory effects of AT2R are mediated 
through inhibition of the phosphorylation and translocation of STAT by nuclear factor-kB 
[121]. In addition, AT2R regulates vasodilation via the activation of bradykinin, NO, and 
subsequently, cyclic guanosine 3′,5′ in the vasculature [122, 123]. Vascular relaxation is 
mediated by AT2R via the PI3K/Akt pathway, which stimulates NO production in vascular 
smooth muscle cells (VSMC) [124]. 
As controversies exist on the specificity of the AT2R agonist Co21 [125, 126], current 
research continues to use an indirect AT2R stimulation approach [127, 128]. While Ang II 
binds to both receptors with nearly the same affinity, AT1R antagonists are used to allow 
investigations on AT2R. In this work, the AT1R antagonist Losartan potassium (2-butyl-4-
chloro-1-[p-(o-1H-tet-razol-5-ylphenyl)benzyl]imidazole-5-methanol mono potassium salt) 
(Los) was used followed by Ang II treatment. This provoked a more than ten-fold increase in 
AT2R mRNA expression level compared to untreated and AT2R-inhibited (AT2R inhibitor 
PD123319) CD117
+
 SC (Fig. 1). An AT1R/AT2R functional crosstalk was already reported 
by Volpe et al. (2003) [129]. They described that an increase of AT2R mRNA expression 
occurred during treatment with AT1R antagonists. Moreover, Maseo et al. (1996) showed an 
inhibitory effect of AT1R on AT2R that was reversible with the AT1R antagonist Losartan 
potassium [130]. 
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5.1 The AT2R in cardiac regeneration 
 
Major actions of AT2R in the injured organism involve anti-inflammation and anti-
proliferation processes. Besides, the high expectations for AT2R in cardiac regeneration were 
based on its expression during development of the fetus, and its re-expression during 
pathological conditions. Even though, the described regulation of AT2R protein expression is 
now questioned, recent research confirms a potential role for tissue regeneration. A non-
cytotoxic CD8
+
AT2R
+
 T cell population was identified mediating anti-inflammatory (via NF-
kB) and cardioprotective actions against ischemic heart injury [121, 131]. The anti-
inflammatory effects of AT2R signaling involve serine/threonine and tyrosine protein 
phosphatases. The blockade of those phosphatases results in reduced TNF-α-induced IL-6 
expression and decreased TNF-α mRNA levels. This was reported for a murine model using 
Co21 and also for human umbilical vein endothelial cells [121].  
It was recently reported that AT2R contributes to cardioprotective cellular mechanisms by 
modulating both T cell and progenitor cell subpopulations in a rat model of MI [110, 131]. In 
studies using transgenic mice that overexpress AT2R in cardiac tissue, a cardioprotective 
effect was mediated via the NO pathway. Moreover, AT2R overexpression was associated 
with improved contractile function in adjacent non-infarcted myocardium [132, 133].  
On the other hand, a negative effect of AT2R expression on cardiac remodeling was described 
in a mouse model. Loss of AT2R signaling (AT2R-knockout mice) was related with 
suppressed tissue fibrosis and abolished hypertrophic responses [134].  
Still, the functions of human cardiac AT2R have not been addressed, and the translational 
relevance of the above mentioned results remains undefined. Thus, the first step to further 
investigate molecular and cellular mechanisms of AT2R actions and their therapeutic 
potential is to reproduce and strengthen findings from a rat model in another animal model.  
 
6 Beneficial combination of CD117 and AT2R for regeneration 
 
A positive role for cardiac repair is ascribed to the CD117 and the AT2R in independent 
research studies. Important signals that increase the regenerative potential of CD117
+
 SC via 
paracrine signaling are still unknown. At the same time, the paracrine effects of AT2R are not 
fully understood. Whether the two receptors will find their way into new therapeutic 
approaches might be influenced by their successful interplay. It was recently shown that a 
 25 
 
CD117
+
AT2R
+
 cell population exists, and increases in response to MI in rats [110]. The rat 
CD117
+
AT2R
+
 cell population showed a significantly increased expression of genes 
associated with self-renewal (c-Myc, Akt) and cardiac differentiation (GATA-4, Nkx-2.5). 
Moreover, these cells attenuate apoptosis of co-cultured cardiomyocytes by phosphorylation 
of STAT-3 and Akt. The above mentioned study was conducted in a single research group in 
a rat model. Thus, the question arises whether the findings are reproducible in a different 
animal model and if the (indirect) stimulation of AT2R on CD117
+
 cells has an influence on 
their potential for regeneration. An improved function of the injured heart would reveal 
beneficial effects of implanted cells. In this context, the promotion of angiogenesis should be 
considered. Stimulation of angiogenesis was shown for CD117
+
 SC and might be their main 
mechanism of action [135]. As for AT2R, a beneficial and an inhibiting influence on 
angiogenesis were reported [136, 137]. Hence, this work addressed the question of the 
inherent properties of CD117
+
 SC with or without AT2R stimulation in regard of a possible in 
vivo application.  
 
7 Electrophysiological investigations 
 
7.1 Molecular basis of patch-clamp recordings 
 
The electrical properties of membranes are valid in all animal cells. They are based on the 
asymmetrical distribution of ions between the cytoplasm and the extracellular space, which 
are separated by the plasma membrane, an effective barrier for charged particles. In general, 
the membrane forms an insulator between two conductors and all three components together 
form a capacitor capable of storing charge. Regarding a biological system, it should be kept in 
mind that 1) the capacitance is proportional to the membrane surface area 2) current is 
proportional to the driving force of ions and 3) current is inversely proportional to the 
resistance of the membrane. The difference of the positive charge outside and the negative 
charge inside of the biological membrane is known as the resting potential of a cell. By 
convention, the reference for potentials in a cell system is the extracellular medium, creating a 
negative resting potential. In animal cells this charge difference is largely driven by passive 
ion movements through ion channels and maintained by electrogenic pumps, such as the 
Na
+
/K
+
 pump or Ca
2+
/Na
+
 exchanger. Ions, namely K
+
, Na
+
, Cl
-
 or Ca
2+
 move down their 
concentration gradient, a movement opposed by an electrical field or the present membrane 
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potential. Any cell establishes an individual resting potential, depending on its ion 
concentration, after an equilibrium condition between electrical gradient (voltage gradient) 
and the ion concentration gradient is reached. The resting potential of most cells is determined 
by the K
+
 gradient and thus, driven towards the K
+
 equilibrium potential (-89 mV; no net flow 
of K
+
). However, any ion can significantly influence the membrane potential if the 
membrane’s permeability for a certain ion changes [138]. The potential at which a certain ion 
gradient is in equilibrium is described by the Nernst equation. Following this equation and 
considering each ion species at a time, the approximate equilibrium potentials are: E(Na)=+60 
mV; E(Ca)=+130 mV; E(K)=-89 mV; E(Cl)=-80 mV [139].  
Ion channels function on the basis of the above mentioned mechanisms and completely differ 
from membrane pumps. They form aqueous pores that connect the intracellular medium with 
the extracellular solution and perform passive transport coupled to the electrochemical 
gradient [140]. Moreover, ion channel types can be distinguished by ion selectivity and 
gating. Opening of a channel is transiently achieved either by a change in membrane potential 
(voltage-dependent), by the binding of a ligand (ligand-dependent; intracellular or 
extracellular), activated by a second-messenger (Ca
2+
 or cyclic nucleotides), activated by 
mechanical tension (stretch-activated) or by membrane-bound G-proteins [139]. The 
repertoire of functioning channels in each cell is enormous and adapted to the special role 
each cell plays in the body. The mechanism of gating corresponds to the channel protein 
confirmation in an open, closed or inactivated state and is a parameter to categorize ion 
channels into families. The two major potassium channel families are voltage-gated potassium 
channels (e.g. delayed rectifier or Ca
2+
-dependent K
+ 
channels) and inward rectifiers (IKir), 
which are voltage-independent. Rectification refers to the property of channels that biases the 
preferred direction of current flow to either the inward or outward direction.  
 
7.2 Patch-clamp technique 
 
In 1991 the Nobel prize was awarded to Erwin Neher and Bert Sakman for developing the 
patch-clamp technique on basis of the one-electrode voltage clamp [141]. According to the 
research question, the cell type and the ion channel(s) under investigation, different patch-
clamp configurations, such as inside-out, outside-out, cell-attached or whole-cell recording 
exist. Patch-clamp is now the basis for most electrophysiological investigations, as it enables 
to record currents through a single open channel. In general, it allows the measurement of 
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currents across the cell membranes, which are mediated by channels and carriers, while 
controlling the membrane voltage. The principle of patch-clamp is to form an extremely high-
resistance seal (up to several Giga Ohm; Gigaseal) by close contact between a previously 
pulled glass capillary (patch-pipette) and the cell membrane. The formed Gigaseal prevents 1) 
leak currents between the pipette and the electrode and 2) the flooding of the cell with 
extracellular bath solution. The cell current can be influenced either by an exchange of the 
surrounding solution or by modulation of the internal capillary solution, which diffuses inside 
the cell. To reach the whole-cell patch-clamp configuration used in this work, the 
approximated membrane patch should be broken by suction or high-voltage pulses after the 
formation of a Gigaseal, making the pipette continuous with the cell. Afterwards, programs of 
specific voltage-steps allow analyzing voltage- and time-dependent changes in membrane 
conductance and the measurement of whole-cell current. The command voltage programs that 
elicit a certain cell current can be adjusted and made to vary over time to study specific 
channel properties and are constantly recorded. The whole-cell current is the product of the 
number of functional channels in the cell membrane, the probability that the “average” 
channel is open and the single-channel current [139]. The current itself is composed of ion-
specific-, leak- and capacitive current [142]. To distinguish the functional ion channel types in 
a cell, ionic current components can be separated from total current, which was described by 
Hodgkin and Huxley and became essential for their description of the course of an action  
potential [143]. Specific inhibitors and enhancers of the ion pathways through the membrane 
are known for most of the investigated ion channels. For instance, K
+
 channels are inhibited 
by tetraethylammonium or cesium, while Na
+
 channels can be inhibited by tetrodotoxin 
extracted from puffer fish. Another successful possibility to isolate ion currents is varying (or 
removing) a specific ion concentration in the extracellular or intracellular solution. However, 
whole-cell patch-clamp has its limitations. One problem is the rundown of currents or channel 
activities owing to the wash-out or diffusion of regulatory components, which is preventable 
with the addition of appropriate agents (e.g. ATP; BAY K 8644) [144].  
 
7.3 Excitable cells  
 
Heartbeat, muscle contraction or the processing of light and color are regulated by specific ion 
channels of excitable cells and the subsequent change of electrical properties. All excitable 
cells, such as neurons, muscle and endocrine cells of animals and some plant cells are capable 
 28 
 
of generating an electrical signal or action potential in response to stimuli of sufficient 
magnitude. An action potential (AP) can be generally defined as a timed cellular event, in 
which the membrane potential of a cell rapidly rises and falls and herein follows a consistent 
trajectory [139]. Moreover, the generation of an action potential is an “all-or-none” event and 
its strength an intrinsic property of each cell. Thus, the intensity of an incoming stimulus can 
only be regulated by the frequency of action potentials fired. In the heart, the APs differ from 
region to region, reflecting the different roles played by the different cell types (compare table 
1). The first description of AP and its generation and propagation was achieved by Alan 
Hodgkin and Andrew Huxley using squid axon [143]. The molecular basis of APs lies in the 
presence of ion channels, specifically voltage-gated ion channels [145]. If a stimulus (e.g. 
mechanical or a neurotransmitter) induces sufficient depolarization of the membrane by 
making the membrane potential more positive, those voltage-gated ion channels open. In 
many excitable cells, voltage-gated Na
+
 channels activate and allow Na
+
 to enter the cell 
down its electrochemical gradient. This creates a positive feedback loop as the further 
depolarization of the membrane activates more Na
+
 channels and enhances depolarization. 
The AP sweeps along the cell as adjacent membrane portions become depolarized. The local 
electrical potential of the excited cell thus shifts from about -70 mV towards the Na
+
 
equilibrium potential (~+50 mV) and reaches a peak phase. Two following mechanisms 
repolarize the excited cell and save it from permanent electrical spasm. Firstly, the automatic 
inactivation of Na
+
 channels, which are consequently unable to re-open, until the cell returns 
to the initial negative membrane potential. And secondly, voltage-gated K
+
 channels open due 
to depolarization, but with slower kinetics than voltage-gated Na
+
 channels [139, 142]. Once 
those delayed voltage-gated K
+
 channels are activated, the K
+
 efflux outruns Na
+
 influx and 
drives the membrane potential back to the initial value (a condition termed hyperpolarization). 
Additional K
+
 efflux further hyperpolarizes the cell and leads to a so-called refractory phase, 
in which no AP can be evoked. The refractory phase is the reason for the unidirectional 
propagation of AP in neurons. Just as voltage-gated Na
+
 channels, K
+
 channels inactivate 
automatically. After a cell-specific time span, the initial resting potential is reached and the 
channels can be activated again. Basically, there are two types of APs; either induced by 
voltage-gated Na
+
 channels or by voltage-gated Ca
2+
 channels. To precisely investigate the 
possible differentiation of SC into excitable cells, it is necessary to distinguish the ionic basis 
of cardiac and smooth muscle APs and mechanism of contraction (Table 1) [146].   
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Table 1 Comparison of action potential (AP) properties in smooth muscle and different types of cardiac muscle [139].  
Feature Smooth muscle  Cardiac muscle –  
SA node/pacemaker  
Cardiac muscle –  
ventricles  
Upstroke of AP  Inward Ca
2+
 current; Ca
2+ 
release  
Inward Ca
2+
 current 
Slow upstroke  
Inward Na
+
 current 
Fast upstroke  
Duration of AP 10 msec 150 msec 250-300 msec 
Ion channels Ca
2+
-activated K
+
 channels 
(BKCa); 
L-type and T-type Ca
2+
 
channels; 
Voltage-gated K
+
 channels  
Slow Na
+
 channels; 
L-type and T-type Ca
2+
 channels; 
Hyperpolarization-activated cyclic 
nucleotide-gated cation channels;  
Delayed rectifier K
+
 channels  
Fast Na
+
 channels; 
L-type Ca
2+
 channels;  
Inward rectifying K
+
 
channels; Delayed 
rectifier K
+
 channels 
 
7.4 Nonexcitable cells 
 
For a long time, nonexcitable cells, such as most of the blood cells, epithelial cells or EC, 
were defined as to lack functional voltage-gated Ca
2+
 channels and fast activated Na
+
 
channels [139]. Consequently, they are unable to evoke regenerative action potentials. 
Nevertheless, the regulation of cytosolic Ca
2+
 levels is the most important response to specific 
stimuli and calcium-dependent K
+
 channels were found in most nonexcitable cells. Thorough 
analysis proved that nonexcitable cells possess nearly all kinds of channels with functional 
importance under physiological conditions. Ion channels found on nonexcitable cells include 
among others: Ca
2+
-activated K
+
 channels, Ca
2+
-activated nonselective cation channels, Ca
2+
-
activated Cl
-
 channels [147], inwardly rectifying K
+
 channels and mechanically activated ion 
channels [139]. Moreover, nonexcitable cells do express voltage-gated ion channels, but do 
not fire action potentials. The functional properties of ion channels in nonexcitable cells 
comprise volume regulation [148], vectorial secretion and reabsorption (e.g. sodium or 
chloride) and regulation of intracellular Ca
2+
 levels [149]. Ca
2+
 channels have a special 
importance because Ca
2+
 entering the cell often plays the role of a chemical messenger to 
activate exocytosis, or secretion, contraction, gating of other channels, ciliary reorientation, 
metabolic pathways as well as gene expression.  
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7.5 Electrophysiological properties of CD117+ stem cells 
 
As mentioned above, electrophysiological properties of implanted cells are crucial in terms of 
safety and to predict electrical coupling to host cells. Knowledge of the initial 
electrophysiological properties of the short-term cultured and CD117
+
 AT2R stimulated stem 
cell population is necessary to draw conclusions on their expectable effects in vivo. 
Especially, as the protein expression of cardiac markers, which is often used to verify the 
differentiation of cells into a specific cell type, does not prove a functional differentiation. 
Differentiation of CD117
+
 SC to cardiomyocytes or smooth muscle cells would yield 
detectable alterations in their electrophysiological properties (compare table 1). Acquiring the 
phenotype of cardiomyocytes should result in the detection of Ca
2+
 and Na
+
 currents [150], 
while the differentiation to smooth muscle cells should develop detectable Ca
2+
 and K
+
 
currents [151]. Besides these two types of muscle cells that form cardiac tissue, the 
differentiation into cardiac or smooth muscle pacemaker or vascular endothelial cells might 
be possible. Electrophysiological investigations of SC were often neglected prior to cell 
transplantation. Few studies report electrophysiological properties of human mesenchymal 
stem cells (hMSC), which were shown to improve cardiac functions upon implantation [152-
154]. In these studies, delayed rectifying K
+
 currents (IKdr), transient outward K
+
 currents (Ito) 
and calcium-activated K
+
 channels (IKCa) were described. Inward currents, such as Na
+
 
currents were mostly absent. 
Previous studies of functional ion channels in mouse cells were designed as a co-culture 
system of murine CD117
+
 SC and rat cardiomyocytes or focused on murine cardiac CD117
+
 
SC [155, 156]. Contrary to mouse MSC, cardiac CD117
+
 SC do not express IKCa [157]. IKdr, 
inward rectifying K
+
 currents (IKir), and volume-sensitive Cl
-
 currents were found, but Ca
2+
 
and Na
+
 currents were absent in both cell types.  The co-cultured CD117
+
 cells expressed 
cardiac markers and Na
+
 and Ca
2+
 voltage-gated ion channels, but functional channels could 
not be detected with patch-clamp recordings. Nevertheless, the ability to develop cytosolic 
Ca
2+
 transients upon membrane depolarization is an essential characteristic of 
cardiomyocytes. In this regard, studies conducted so far exclude the transdifferentiation into 
cardiac myocytes in culture [156, 158]. Interestingly, ion channels of freshly isolated murine 
bone marrow CD117
+
 SC, especially prior to implantation, lack proper descriptions.  
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Aim of the study 
 
Understanding the stem cell mechanism of action contributing to cardiac regeneration and 
exploring stem cells for a safe implantation is crucial for the development of novel successful 
stem cell therapies.  
This work demonstrates an assessment of the functional characteristics of CD117
+
 SC under 
normal and AT2R stimulated conditions. The purpose was to thoroughly analyze their in vitro 
and in vivo capacities with regard to cardiac regeneration. Stem cell effects were investigated 
in previous studies, but lack consistent descriptions especially on a functional level.  To the 
best of our knowledge, electrophysiological properties of CD117
+
 BMSC were investigated 
for the first time. This aimed to prove differentiation on a functional level and to estimate 
risks following implantation. Supporting in vitro experiments endeavored to characterize 
CD117
+
 SC in terms of a potential differentiation to cardiomyocytes, smooth muscle cells or 
endothelial cells. Molecular biological techniques were used to observe changes on a 
transcriptional (qRT-PCR) and functional (FACS, 2-D Matrigel assay, Immunocytochemistry, 
acLDL assay) level and to detect influences of CD117
+
 SC on cardiomyocytes survival in 
vitro. Finally, a mouse myocardial infarction model was the method of choice to detect effects 
of CD117
+
 SC implantation and the impact of their AT2R preconditioning on cardiac 
regeneration.  
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Results and Discussion 
 
1 Electrophysiological properties indicate an endothelial cell-like differentiation 
 
The proposed transdifferentiation of CD117
+
 SC into cardiomyocytes requires an 
investigation of their functionality. Besides the expression of cardiac markers found with 
immunohistochemistry, functional ion channels are a major prerequisite to truly prove 
differentiation. Whole-cell patch-clamp technique was utilized to determine the 
electrophysiological properties of isolated murine CD117
+
 BMSC with and without 
stimulation of AT2R for 3 days [127, 159]. At potentials between -80 mV and +10 mV, 
current recordings did rarely exhibit time-dependence and currents recorded after the 
capacitive current did not show visible channel openings. At more positive potentials, slow 
activation of currents was observed, which fully established after 300–400 ms. At very 
positive potentials, large outward current deflections, probably opening BKCa channels, were 
detectable in a small fraction of CD117
+
 SC. The most dominant current component 
discovered in CD117
+
 SC was an inwardly rectifying K
+
 current (IKir). The size of this current 
could be greatly increased by a fast exchange of extracellular solution (to K
+
-rich and Na
+
 
low), which changed the reversal potential of the total current from -31.9±6.8 mV to +2.5±6.2 
mV (n = 9) indicating a major influence of K
+
 on total current (Fig. 1; taken from [127]). Of 
note, a previously reported delayed rectifying K
+
 channel in CD117 cardiac SC was absent 
[155]. Outward rectification was less expressed and no major chloride channel was detectable. 
Blockade of hyperpolarization-activated cyclic nucleotide-gated cation channels (HCN) with 
ZD7288 partly reduced the inwardly directed current (control: 45.7± 14.8 pA/pF; ZD 7288, 
10 µM: 28.5±10.9 pA/pF) [127]. The current flowing through HCN channels is also called 
funny current or pacemaker current (If) and plays a key role in cardiac pacemaker cells. 
Stimulation of AT2R did not alter electrophysiological properties of CD117
+
 SC. Even 
though few studies reported an influence  
of Ang II on BKCa channels via the activation of arachidonic acid, it is imaginable that those 
channels are not sufficiently expressed on the investigated CD117
+
 SC [160, 161]. The 
presented results deliver high evidence that CD117
+
 BMSC will not differentiate into 
cardiomyocytes under the given culture conditions. The sufficient increase of detected time-
dependent inward currents in vivo and the development of APs are unlikely.  
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A further aim was to evaluate the per se properties of CD117
+
 SC in respect to Ca
2+
 current 
activation and in comparison to vascular smooth muscle cells (VSMC) of the portal vein of 
guinea pig. The species difference has no influence on the obtained results, since cell type 
specific ion and channel properties are conserved between species. We could prove that 
inward Ca
2+
 currents in CD117
+
 SC were at least ten times smaller than those of VSMC and 
the absolute size of current flow 30 times larger in VSMC (Fig. 2; taken from [159]).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1 Current recordings during fast exchange of the external solution.  
Replay of a current trace recorded in CD117+ SC for two different holding potentials and exchange of the external solution 
to high K+ and low Na+. The influence of the K+-rich solution on the holding current (arrows under the bracket show start 
of 10-s ejection pulses) and the elicited currents are presented. The arrow at the left side indicates zero current and gives a 
size of 100 pA/pF. Washout of K+-rich solution returns the holding current to control levels (A). Superposition of the 
current traces (500 ms) elicited by the 10 mV increments of the test potential (starting at -80 mV). The numbers near the 
traces correspond to the traces in A (B). Current–voltage relationship investigated with the same paradigm. Data given as 
mean ± SEM; n = 9 (C). 
Figure 2 Comparison of inward currents of VSMC 
and CD117+ SC.  
Peak inward currents of the individual I-V curves were 
determined at individual potentials. Analyzed time 
points were 5, 30 and 300 ms of each evaluated cell. 
Data given as mean ± SEM. 
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Moreover, other depolarizing currents (e.g. Na
+
 currents) were absent.  The application of 
barium instead of Ca
2+
 -as charge carrier for current through voltage-dependent Ca
2+
 
channels- evoked no increase in the time-dependent currents, which were determined at 
different time points. In CD117
+
 SC, the time-dependent inactivation was slower and the 
voltage-dependent activation was also reduced in respect to time (Fig. 3; taken from [159])  
 
  
Figure 4 Ion channel mRNA expression of 
CD117
+ 
SC.  
Kir2.1, HCN and KCa channel mRNA expression 
in freshly isolated and 3-day cultured CD117
+
 SC 
± AT2R stimulation (Ang II/Los).  Kir2.1 mRNA 
expression was significantly increased after 3d. 
The presence of KCa and HCN mRNA is not 
altered. Expression levels were normalized to the 
expression of GAPDH. Data given as mean ± 
SEM; n = 5; *p < 0.05.  
Figure 3 Representative current-voltage relationships of a VSCM (A) and a CD117
+
 stem cell (B).  
In both examples the holding potential was -60 mV and test potentials followed a pre-pulse to -90 mV. Current 
size was evaluated after 5 ms (square), 30 ms (triangle) and 300 ms (circle) after the depolarizing pulse. In the 
SC, current activation was slower than in VSMC and rapid activating Na
+
 current was absent. Typical activation 
threshold of -30 mV was present in both cell types indicating the existence of L-type Ca
2+
 channels.  
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Additionally, analysis of mRNA expression of selected ion channels was done to refine patch-
clamp results and to possibly show changes provoked by AT2R stimulation on the 
transcriptional level (Fig. 4; taken from [127]). The IKir 2.1, which is especially expressed on 
ventricular myocytes, was significantly increased in CD117
+
 SC in culture if compared to 
freshly isolated cells. HCN and calcium-dependent K
+
 channels were present (IKv), but their 
expression was not altered following culture (Fig. 4). No significant changes following 
stimulation were found for the analyzed channels. 
In the two patch-clamp studies, to our knowledge we provide the first thorough investigation 
of CD117
+
 BMSC prior to implantation. The combined results indicate a development of 
CD117
+
 SC into an endothelial-like phenotype. This in turn would point to the hypothesis of 
paracrine effects supporting angiogenesis and improving myocardial functions. Our results 
further indicate that CD117
+
 SC implantation is safe regarding misguided electrotonic 
coupling or signaling and that those cells are unlikely to produce arrhythmias in vivo. The 
findings of basic investigations in vitro and the known difficulties of implantation studies 
eventually suggest a low incorporation of those cells in the murine heart. However, regarding 
the obtained in vitro results, CD117
+
 SC might physically contribute to the maintenance of 
cardiac function and improve neovascularization. 
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2 CD117+ stem cells develop into an endothelial cell-like phenotype in vitro 
 
Many lines of investigation point to a differentiation of CD117
+
 SC to an endothelial-like 
phenotype in vitro [96, 135, 162]. This supports the hypothesis of paracrine signaling upon 
implantation. In the present work, CD117
+
 SC cultivated for three days, with or without 
AT2R stimulation, were compared to freshly isolated control cells. Influences of the AT2R on 
CD117
+
 SC were investigated. The efficiency of AT2R stimulation was verified by qRT-
PCR, showing an 11.38 ± 2.71-fold increase in AT2R mRNA expression compared to 
unstimulated control cells (Fig. 5; taken from [163]).  
 
Following AT2R inhibition with its antagonist PD123319, AT2R mRNA was detectable in 
only 2 out of 5 CD117
+
 SC samples. The addition of PD123319 to CD117
+
 SC downregulated 
AT2R mRNA levels to those observed in control cells and showed that increased expression 
of AT2R mRNA in CD117
+
 SC is not an inherent property, but can be induced (Fig. 5). 
FACS analysis of stem cell marker expression showed a significant decrease of stem cell 
marker Sca-1 and CD34 and a significant increase of the hematopoietic marker CD45 upon 
cell culture, independent of stimulation for the AT2R This points to less immature cells and 
might be a hint for differentiation in culture (Table 2). 
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Figure 5 Quantitative real-time PCR analysis of AT2R mRNA . 
CD117
+
 SC were treated with Ang II/Los or PD123319 for 24h. Only 2 out of 5 experiments showed AT2R 
expression after PD123319 treatment. The mean mRNA expression levels of untreated control CD117
+
 SC 
were arbitrarily given a value of 2
0
. Expression levels were normalized to the expression of GAPDH. Data 
given as mean ± SEM; n=5.  
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Table 2 Immunophenotypic analysis of CD117+ SC (freshly isolated and after 3d of culture ± Ang II/Los). 
Antibody Fresh (n=8) 3 days (n=5) 3 days +Ang II/Los (n=5) 
CD45 77.38 ± 1.81 99.98 ± 0.02 
*
 99.96 ± 0.02 
*
 
CD34 14.65 ± 1.62 4.88 ± 1.3 
#
 4.48 ± 0.81 
#
 
Sca-1 11.85 ± 1.37 3.7 ± 0.46 
#
 4.18 ± 0.69 
#
 
 
 
A differentiation into an endothelial-like cell type was first of all found by the expression of 
endothelial marker CD31 and VEGF in single culture (compare with [127]). Moreover, the 
uptake of acetylated low density lipoprotein (acLDL) is a widely used assay to analyze 
endothelial cell properties. The acetylation of the lysine residue of LDL prevents the binding 
of the LDL complex to its receptor. EC are capable of taking up this acetylated protein 
because of their “scavenger” receptors. Compared to freshly isolated CD117+ SC, cells in 
culture showed an increased uptake of acLDL –independent of stimulation for the AT2R (Fig. 
6A; taken from [127]) .  
In addition, a 2-D Matrigel in vitro assay was deployed to investigate influences of 
stimulation on cell alignment and cell morphology. The elongation ratio (length to width) of 
Ang II/Los stimulated cells is significantly increased compared to control and PD123319 
treated cells (Fig 6B; taken from [163]). Cell alignment and sprouting was also increased 
following Ang II/Los addition compared to control and PD123319 treated cells [163].  
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Figure 6 Analysis of endothelial properties of CD117
+
 SC. 
Quantitative analysis of acetylated low density lipoprotein (acLDL) uptake of freshly isolated and 3-day cultured 
CD117
+
 SC. AcLDL (Alexa Fluor488) uptake of living cells was measured and analysed with FACS BD LSR II. 
Three subpopulations (negative, low and bright uptake) were distinguishable in respect to the fluorescence 
intensity. Total acLDL uptake is composed of the low and bright subpopulations. After 3 days CD117
+
 SC 
showed a significant uptake of acLDL compared with freshly isolated cells. n=5–6; *p < 0.01 vs. fresh CD117 
(A). The ratio length to width was analyzed as a measure of cell elongation. Five cells in each 5 random fields of 
view were blindly assessed in three independent experiments. The influence of AT2R treatment and inhibition 
was compared to control CD117
+
 SC. n=3;*p<0.001 vs. CD117 control; #p<0.05 vs. CD117 +PD 123319 (B). 
Data given as mean ±SEM.  
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Besides those results in a single culture, a co-culture setup was used to approximate the 
situation in vivo. The co-culture experiments were largely conducted by Steffen Müller under 
my supervision and were published in his diploma thesis [164]. The commercially available 
AT-1 mouse atrial cardiomyocyte tumor lineage-derived cell line HL-1 [165] was cultured 
together with CD117
+
 SC in a ratio of 1:2 with or without the stimulation of AT2R under 
either normoxic or hypoxic conditions. We confirmed that HL-1 cells express cardiac markers 
and assessed their viability under various conditions. As expected, hypoxia significantly 
reduced the viability of HL-1 cells. The stimulation with Ang II, Los or both had no 
significant effect on the investigated parameters. In contrast, Wange et al. found that the 
apoptotic rate of HL-1 cells increased under anoxic condition (no oxygen) following 
treatment with Ang II. This effect was reversed when Los was added to the HL-1 culture 
[166]. 
Upon co-culture, CD117
+
 SC expressed endothelial cell surface markers VEGF and CD31 
and, to a certain extent the cardiac transcription factor Mef2-B. Troponin-I or α-smooth 
muscle actin expression was not detectable [164].   
Further, the influence of CD117
+
 SC (± Ang II/Los) on HL-1 vitality and viability was 
analyzed.  Vitality of HL-1, measured as the enzymatic conversion of MTT, showed a 
significant increase when directly co-cultured with CD117
+
 SC under normoxic and hypoxic 
conditions (Fig. 7A; taken from [163]). However, additional stimulation for the AT2R 
attenuated this effect. Viability of Hl-1 cells was not significantly influenced by CD117
+
 SC 
(± Ang II/Los) (Fig. 7A). The applied approach of subjecting a co-culture to hypoxia differs 
from the in vivo situation. In implantation studies, SC are injected after MI after the hypoxic 
Figure 7 HL-1 vitality in single culture and co-culture with CD117+ cells (±Ang I/Los).  
Bar charts illustrate HL-1 vitality determined by MTT –assay after 48 hours in culture with or without the addition of 
CD117 + SC. Hypoxia treated groups underwent oxygen deprivation for 24h. A significant increase of HL-1 vitality was 
detectable following CD117 addition, if cells were cultured with cell-to-cell contact (n=4, in duplicates) (A), but not if an 
inlet filter was used, which prevented HL-1 and CD117+ SC cell-to-cell contact (n=2, in duplicates) (B). Data given as 
mean ± SEM; **p<0.01 vs. normoxic HL-1 group; *p<0.05 vs. hypoxic HL-1 group. 
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environment is established. Moreover, SC are delivered to the border zone of the infarct and 
might not be directly influenced by the prevalent lack of oxygen supply. Limitations of the 
present in vitro study are the simultaneous treatment of HL-1 and CD117
+
 SC and the lack of 
further stimuli from the microenvironment. However, it appears that direct cell-to-cell contact 
and interaction rather than exclusive cytokine secretion is responsible for the increased 
vitality under hypoxia. If the two cell populations are separated by an inlet filter, but cultured 
in the same medium, no positive effect on HL-1 vitality under hypoxia was observed (Fig. 
7B; taken from [163]) [163]. In a recent study, a co-culture of HSC with neonatal rat 
ventricular myocytes showed that direct cell-to-cell contact induces anti-apoptotic pathways 
in HSC and indicated cardioprotective effects of HSC on cardiomyocytes [167]. This is in line 
with our findings and points to a beneficial effect of CD117
+
 BMSC on the survival of 
cardiomyocytes.   
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3 Implantation of CD117+ stem cells significantly improved cardiac functions  
 
Transgenic mice, with Enhanced Green Fluorescent Protein (EGFP) cDNA under the control 
of a chicken β-actin promoter and cytomegalovirus enhancer, were used to isolate donor cells 
(Charles River, Germany). In a first step, the EGFP expression of CD117
+
 SC of BM and lung 
as well as mononuclear cells (MNC) isolated from spleen and thymus was analyzed with flow 
cytometry. Limitations of those transgenic mice, regarding their inconsistent EGFP 
expression, were previously described for HSC and questioned an application for 
transplantation studies [168]. We found that only 35.3±2.4 % of magnetic activated cell 
sorting-isolated CD117
+
 BMSC expressed EGFP in contrast to 87.5±6.8 % of lung CD117
+
 
SC (n=5) [163]. MNC of thymus and spleen showed an EGFP expression of 22.5±2.7 % and 
58.4±6.3 %, respectively.  This analysis showed that the EGFP expression was somewhat 
impeded in these BMSC and ubiquitous EGFP expression was not given in the investigated 
transgenic mice. In a second step, CD117
+
 BMSC were purified for their expression of EGFP 
with FACS Aria (BD Bioscience). The purified population (re-analysis: 85.7 % viable 
EGFP
+
) was subjected to CFU colony forming assay in order to detect if cells maintain EGFP 
expression during culture and differentiation for 12 days. Afterwards, only 49.5±8.1 % of the 
viable cells (n=2) still expressed EGFP as determined by flow cytometry. Transferring these 
results to the in vivo situation makes it likely to underestimate cell retention, since EGFP 
negative donor cells cannot be distinguished from host cells (male donor, male recipient). 
Owing to the low cell yield, purifying EGFP
+
CD117
+
 BMSC with FACS prior to 
implantation was not feasible. Hence, the number of detected cells ex vivo had to be 
extrapolated from the FACS analysis and quantitatively assessed with qRT-PCR. 
The implantation method was tested in advance using CFDA-SE dye stained C2C12 mouse 
myoblast cell line and stained cells were found in all three injection sites after 24 h. Retrieval 
of EGFP
+
CD117
+
 BMSC was tested 24 and 48 h and 3 weeks after implantation. Few cells 
were found after 24h, while no EGFP signal was detectable after 48 h and 3 weeks, 
respectively. Ex vivo analysis of implanted cells in cardiac tissue showed co-localization of 
EGFP and VEGF as well as EGFP and CD34. 24 hours after implantation, the number of 
retrieved cells was similar after injection into a recipient mouse with MI compared to a sham-
operated animal. However, compared to the injected cell number (2x10
^5
) the recovered cells 
found in frozen tissue sections was considerably low. Many studies point to cell retention as a 
major problem. If cells are injected with NaCl (0.9%), up to 95% of cells are lost during the 
first 25 minutes [100]. Moreover, cell retention after three weeks is limited because of the 
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hostile environment offered in the infarcted area, which lacks supporting cells or tissues, 
oxygen or nutritive substrates, but contains an excess of neutrophils and scavenger cells. 
Considering this and the low expression of EGFP in CD117
+
 SC gives a reasonable 
explanation for the remarkable loss of implanted cells. We could show that CD117
+
 BMSC 
display inconsistent EGFP expression in the investigated transgenic mice strain, which 
hampers cell retention analysis.  
To analyze a possible improvement of cardiac functions, experimental MI was induced in 
C57BL/6J recipient mice and CD117
+
 BMSC from EGFP
+
 C57BL/6J donor mice were 
implanted into the infarct border zone. Despite the inconsistent EGFP expression as 
determined with FACS, we decided to use EGFP
+
CD117
+
 cells. In two independent 
experiments we found that protein expression (FACS) did not match mRNA levels. Only 50% 
of purified EGFP
+
CD117
+
 cells subjected to CFU still expressed EGFP protein after 12 days, 
but mRNA analysis showed that the relative EGFP mRNA expression was as high as in the 
positive control (EGFP
+
 heart) and thus, investigation of EGFP mRNA might more closely 
resemble the magnitude of recovered cells. The experimental set-up is shown in table 3.  
 
Table 3 Set-up of in vivo experiments (Permanent Ligation) 
Group Experimental Procedure 
Sham Thoracotomy and Matrigel™ implantation 
MI-C Thoracotomy, LAD ligation, Matrigel™ implantation 
MI-CD117 Thoracotomy, LAD ligation, 24h incubated CD117+ SC in Matrigel™ implantation 
MI-CD117 +AngII/Los Thoracotomy, LAD ligation, 24h AT2R stimulated CD117+ SC in Matrigel™ 
implantation 
 
The left ventricular remodeling process in mice is largely completed after three weeks [169] 
and catheter-conductance method was consequently applied to determine cardiac function via 
pressure and volume parameters. The pressure/volume loop measurements were recorded 
under normal (baseline) and stress (dobutamine) conditions after calibration (pressure and 
volume) and correction of the volume signal for wall conductance (parallel volume). Under 
both conditions, the implantation of CD117
+
 SC seems to improve left ventricular functions 
(Fig. 8; taken from [163]). The ejection fraction and cardiac output were significantly 
increased if the two cell-injected groups were compared to the MI-C group (Fig. 8B+C). 
Heart weight/body weight ratio, which is a commonly used index of cardiac hypertrophy, 
decreased in the groups with implanted cells (Fig. 9A; taken from [163]). Mortality improved 
as well, but was not significantly different as determined with Log-rank (p=0.209 MI+ 
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CD117+Ang II/Los compared to MI-C) and Gehan-Breslow-Wilcoxon test (p=0.171 
MI+CD117+Ang II/Los compared to MI-C) (Fig. 9B; taken from [163]).  
 
 
In addition to functional tests, hearts and lungs were explanted after termination of the 
experiment and frozen histological sections of hearts were prepared. Heart tissue, comprising 
part of the infarcted area, and the lung was used for RNA isolation and qRT-PCR analysis to 
assess cell retention and the escape of implanted cells from the heart towards the lung. The 
implantation of CD117
+
 SC resulted in a significantly increased capillary density (Fig. 10; 
taken from [163]) and a significantly decreased collagen deposition (Fig. 11; taken from 
Figure 8 Cardiac functions 3 weeks after MI.  
Left ventricular functions at both baseline and stress (dobutamine) conditions were assessed by catheterization. Maximal 
intraventricular developed pressure was increased in both SC implanted groups compard to MI-C (A).  Ejection fraction and 
cardiac output was significantly increased in MI-CD117 and CD117 +Ang II/Los group, respectively, under both conditions 
(B+C). Data given as mean ± SEM; n=6; *p<0.05; **p<0.01 vs. MI-C. 
Figure 9 Improved heart to body weight ratio and mortality 3 weeks after MI.  
Statistical analysis showed the tendency of improved heart to body weight ratio following SC implantation, which was 
however not statistical significant (Student’s t-test) (A). Therapy related survival rates [%] did not significantly differ among 
the MI groups as determined with Log-rank and Gehan-Breslow-Wilcoxon test (B). Data given as mean ± SEM.  
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[163]) independent of stimulation. This correlates with improved LV- functions and might be 
attributable to paracrine effects of CD117
+
 SC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Even though EGFP
+
 cells were not detectable using immunohistochemistry, EGFP mRNA 
expression was measurable with qRT-PCR three weeks after MI (Fig. 12F). The migration of 
Figure 10 Increased capillary density in remote area of infarct zone. 
Representative biotinylated tomato lectin perfusion staining in remote area of infarct zone of each group. Bound lectin was 
stained with AlexaFluor 568 secondary antibody (A). Capillary density in the remote area is significantly increased 
following SC implantation 3 weeks after MI (B). Data given as mean ± SEM. *p<0.01 vs. MI-C; n=5  
 
Figure 11 Collagen deposition in remote area and border zone of infarct. 
Representative Fast Green FCF (myocytes)/Sirius Red (fibrosis) stainings at the border zone of the infarcted area (A). 
Collagen deposition is significantly decreased in the remote area and border zone of infarct in both SC treated groups 3 
weeks after MI (B). Data given as mean ± SEM. *p<0.05, **p<0.01 vs. MI-C; n=6  
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intramyocardially implanted cells into filter organs such as the lung is an acknowledged 
process [170]. EGFP mRNA expression was found in the heart sections and correlates with 
the expression found in lungs (Fig.12F). Quantification of the total EGFP mRNA amount was 
impeded by the co-use of explanted hearts for cryosections and RNA analysis. However, after 
three weeks SC were still present in the heart, which correlates to the observed functional 
improvements.  
Analyses of gene expression revealed influences of implanted cells in the heart three weeks 
after MI (Fig. 12; taken from [163]). The expression of AT2R mRNA in both SC treated 
groups was visibly increased compared to MI-C. Due to the high standard deviation, 
differences lack significance (Fig. 12A). The upregulation of eNOS expression was shown to 
improve the migratory capacity of bone marrow–derived stem cells [49] and eNOS was 
reported to be involved in increased BMSC migration following AT2R stimulation [171]. 
After three weeks, eNOS mRNA expression in hearts injected with CD117 +AngII/Los was 
significantly lower than after CD117
+
 SC implantation (Fig. 12C). Regarding BMSC 
migration, we could not find significant differences in mRNA levels of CD34 stem cell 
marker (not shown) or stem cell homing factor CXCL12 (SDF-1) (Fig. 12E). We speculate 
that SC migration is an immediate process, which is not subjected to changes in chronic 
ischemia and not associated with eNOS regulation at later time points. Moreover, eNOS is 
required as a sensor for physiological vascular adaptation to blood flow, thus, increased eNOS 
expression might have contributed to increased capillary density.  
MMP-2 is a key factor for micro-environmental adhesion, maturation and differentiation of 
stem cells [47], but also for the breakdown of extracellular matrix in normal physiological 
processes and tissue remodeling. Controversies exist on the regulation of MMP-2 after MI. 
Studies suggest that inhibition of MMP-2 activity improves the survival rate after acute MI by 
preventing cardiac rupture and delays post-MI remodeling through a reduction in macrophage 
infiltration [172]. Interestingly, blockade of both Ang II receptors resulted in increased 
stiffness, fibrosis and increased MMP-2 activity, which was reversed with AT1R blockers 
[173, 174]. This is in line with the present work, as stimulated CD117
+
 SC provoked 
remarkably decreased MMP-2 mRNA levels (Fig. 12D). To estimate a potential pro-survival 
effect of implanted cells, we analyzed mRNA levels of anti-apoptotic Bcl-2 and pro-apoptotic 
Bax (Fig. 12B). A reduced Bax/Bcl-2 ratio was reported to alleviate cardiomyocyte apoptosis. 
Increased Bcl-2 levels in the acute stage of MI and upregulation of Bax expression by chronic 
cellular responses of the affected myocytes against (mechanical) stress was reported 
previously [175]. Bax/Bcl-2 ratio was significantly decreased in the SC implanted groups, 
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when compared to MI-C (Fig. 12B), pointing to long-term anti-apoptotic effects after SC 
administration [163]. 
 
  
Figure 12 Quantitative real-time PCR analysis of heart sections three weeks after MI. 
qRT-PCR analysis for AT2R (A), Bax/Bcl-2 (B), eNOS (C), MMP-2 (D), CXCL12 (E) and EGFP (F) genes, respectively in 
heart sections. SC implantation upregulates AT2R as well as eNOS and downregulates Bax/Bcl-2 ratio and MMP2 
expression. EGFP gene levels are given as ΔCt (cycle threshold difference between EGFP and GAPDH) as EGFP is not 
expressed in Sham and MI-C. Otherwise, the average mRNA expression level in the Sham hearts was arbitrarily given a 
value of 1 (20). Expression levels were normalized to the expression of GAPDH. Data given as mean ± SEM; n=6, *p<0.05 
vs. MI-C; #p<0.05 vs. MI-CD117.  
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Conclusions 
 
The presented work aimed to assess the potential of CD117
+
 BMSC to contribute to cardiac 
regeneration after MI. Of particular interest were the evaluation of safety and the retention of 
cells participating in functional improvements. With the two patch-clamp studies and 
supporting in vitro experiments, we provide the first thorough investigation of CD117
+
 BMSC 
prior to implantation. The combined in vitro results indicate a development of CD117
+
 SC 
into an endothelial-like phenotype, but exclude a transdifferentiation into cardiomyocytes or 
smooth muscle cells. Our results further show that CD117
+
 SC implantation is safe regarding 
misguided electrotonic coupling or signaling and, that those cells are unlikely to produce 
arrhythmias or APs in vivo. Of note, it is also unlikely that CD117
+
 SC will contribute to 
mechanical contraction of the heart.   
The analysis of EGFP mRNA levels indicated that the implanted CD117
+
 SC physically 
contributed to the maintenance of cardiac function and improved neovascularization. The 
implanted SC supported cardiac function via paracrine stimulation of angiogenesis and acted 
cardioprotective as indicated by increased eNOS and decreased Bax/Bcl-2 ratios. Importantly, 
the stimulation of AT2R on CD117
+
 SC provoked no additional improvement of cardiac 
functions, fibrosis or capillary density. Benndorf et al. (2010) even showed a negative 
influence on remodeling after pharmacological AT2R stimulation in a murine infarct model 
[176].  In contrast, a recent study showed significantly enhanced vessel density four weeks 
after MI as well as reduced cardiomyocyte apoptosis and inflammation three days after the 
implantation of AT2R stimulated BMSC into the infarct border zone in rats [171]. Species 
differences, SC population and variation in experimental setups -in terms of stimulation- 
might contribute to the different outcomes and hamper a thorough comparison. Moreover, it 
has to be considered that the RAS is activated following MI and that the endogenous 
activation of AT1R/AT2R might cover specific effects of CD117
+
AT2R stimulated SC 
leaving this experimental group without significant effects in vivo. The significant increase of 
cell alignment and cell elongation after AT2R stimulation in vitro, pointed to a mechanism of 
action that might be masked by AT1R related-effects in vivo. Furthermore, a recent study 
proposed that a beneficial or detrimental effect of AT2R during myocardial regeneration is 
largely dependent on expression levels [177]. A defined cardiac-selective overexpression of 
AT2R was previously shown to protect heart functions from ischemic injury [178]. It is hence 
imaginable, that in addition to SC implantation, the intramyocardial application of AT2R 
agonists or AT1R antagonists would yield significant improvements.  
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A regenerative potential of the CD117
+
 SC population might be attributed to their 
differentiation into an endothelial-like phenotype and to enhanced paracrine effects, such as 
the secretion of VEGF. Importantly, this hypothesis was supported by patch-clamp 
measurements presented here. The improved cardiac function might be a result of 
cardioprotective actions of CD117
+
 SC and not their electromechanically coupling to native 
cells. Positive effects could not be ascribed to the AT2R, as stimulation of CD117
+
 SC might 
not be sufficient to completely up-regulate functions covered by the AT2R. The influence of 
the AT2R seems to be subjected to a complex regulation and is likely dependent on the 
AT1R/AT2R crosstalk [179]. Therefore, it will be crucial to analyze the mechanisms 
underlying AT2R function in the interplay with its opposing receptor AT1.  
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